Authors
Petrachkov D.V., Zenkin N.S., Subbot A.M., Chizhonkova E.A., Khanova A.N., Altemirova Kh.Kh., Panova A.D.
M.M. Krasnov Research Institute of Eye Disease, Moscow
Abstract
This review examines the role of cytokines, growth factors, and multimodal imaging in the pathogenesis and prognosis of proliferative diabetic retinopathy (PDR). PDR is characterized not merely as a microangiopathy, but as a chronic neuroinflammatory, fibrovascular disease, with the vitreous body serving as a reservoir for locally produced mediators. The review systematizes data on angiogenic factors (VEGF-A, PlGF, HGF), anti-angiogenic factors (PEDF, sFlt-1), pro-inflammatory cytokines (IL-6, IL-8, IP-10, MCP-1), pro-fibrotic factors (CTGF, TGF-β2, PDGF-BB, bFGF), and emerging mediators (IL-15, IL-16, G-CSF, MIP-1α/β). It highlights VEGF-independent mechanisms–such as IL-6 and IL-8 trans-signaling–as well as the contributions of systemic factors and glycemic control. The capabilities of intraoperative OCT (iOCT), OCT, OCT-angiography (OCT-A), and microperimetry are discussed, alongside the impact of vitrectomy on the cytokine profile and the prognostic significance of the IL-6/sIL-6R complex. The necessity for prospective evaluation of changes in the cytokine profile and imaging data to predict clinical outcomes is underscored.
Conclusion. PDR is a polyetiological, fibrovascular process mediated by a network of angiogenic, pro-inflammatory, and pro-fibrotic cytokines that are produced locally and concentrated within the vitreous body. Multiplex analysis and OCT/OCT-A can identify molecular and structural biomarkers; however, most studies are cross-sectional and do not establish long-term prognostic value. It remains unclear how the baseline cytokine profile and intraoperative structural data might predict specific postoperative outcomes.
Keywords: proliferative diabetic retinopathy, cytokines, vitreous body, optical coherence tomography, vitrectomy.
References
1. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.
2. Milenkaya TM, Bessmertnaya EG, Aleksandrova VK, et al. Diabetic retinopathy. Diabetes mellitus. 2005; 8(3): 18–20. (In Russ.)
3. Budzinskaya MV, Petrachkov DV, Savochkina OA, Arzhukhanov DD. On the issue of classifying diabetic retinopathy. Vestnik ofhthalmology. 2019; 5: 272–277. (In Russ.)
4. Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018; 19(4): 942.
5. Bianco L, Arrigo A, Aragona E, et al. Neuroinflammation and neurodegeneration in diabetic retinopathy. Front Aging Neurosci. 2022; 14: 937999.
6. Yusef Yu, Petrachkov DV, Baryshev KV, Matyushenko AG. The effect of vitrectomy on changes in the content of molecular biomarkers in the vitreous cavity in the early postoperative period in patients with proliferative diabetic retinopathy. Vestnik ofhthalmology. 2025; 141(2): 30–36. (In Russ.)
7. Iyer SSR, Lagrew MK, Tillit SM, et al. The Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease. Int J Mol Sci. 2021; 22(13): 7142.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22): 1480-1487.
9. Gong QY, Hu GY, Yu SQ, et al. Comprehensive assessment of growth factors, inflammatory mediators, and cytokines in vitreous from patients with proliferative diabetic retinopathy. Int J Ophthalmol. 2022; 15(11): 1736-1742.
10. Mason RH, Minaker SA, Lahaie Luna G, et al. Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis. Eye. 2022. doi: 10.1038/s41433-022-02127-x.
11. Khaliq A, Foreman D, Ahmed A, et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest. 1998; 78(1): 109-116.
12. Kahtani EA, Xu Z, Al Rashad S, et al. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye. 2017; 31(4): 529-536.
13. Wu G, Liu B, Wu Q, et al. Correlations Between Different Angiogenic and Inflammatory Factors in Vitreous Fluid of Eyes With Proliferative Diabetic Retinopathy. Front Med. 2021; 8: 727407.
14. Neroev VV, Zaitseva OV, Balatskaya NV, Lazutova AA. Local and systemic production of 45 cytokines in complicated proliferative diabetic retinopathy. Medical Immunology. 2020; 22(2): 301-310. (In Russ.)
15. Simó R, Vidal MT, García-Arumí J, et al. Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: A case-control study. Diabetes Res Clin Pract. 2006; 71(1): 36-44.
16. Ogata N, Nishikawa M, Nishimura T, et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002; 134(3): 348-353.
17. Trunov AN, Varvarinsky EV, Chernykh VV, Smirnov EV. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015; 63(1): 33-36.
18. Wu F, Phone A, Lamy R, et al. Correlation of aqueous, vitreous, and plasma cytokine levels in patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2020; 61(2): 26.
19. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003; 110(9): 1690-1696.
20. Yoshida S, Kubo Y, Kobayashi Y, et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. Br J Ophthalmol. 2015; 99(7): 960-966.
21. Liu J, Yu M, Yan J, et al. The association between glycated hemoglobin and intraocular inflammatory factors in patients with proliferative diabetic retinopathy. Int J Retina Vitreous. 2025; 11(1): 115.
22. Jung M, Ness JN, Schwammle ME, et al. IL-6 trans-signaling: an overlooked driver of retinal neovascularization? Angiogenesis. 2026; 29: 11. doi: 10.1007/s10456-025-10022-8.
23. Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011; 55(3): 256-263.
24. Loukovaara S, Piippo N, Kinnunen K, et al. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol. 2017; 95(8): 803-808.
25. Loporchio DF, Tam EK, Cho J, et al. Cytokine Levels in Human Vitreous in Proliferative Diabetic Retinopathy. Cells. 2021; 10(5): 1069.
26. Yoshida A, Yoshida S, Khalil AK, et al. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci. 1998; 39(7): 1097-1106.
27. Descamps FJ, Martens E, Kangave D, et al. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res. 2006; 83(2): 401-407.
28. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One. 2008; 3(7): e2675.
29. Klaassen I, van Geest RJ, Kuiper EJ, et al. The role of CTGF in diabetic retinopathy. Exp Eye Res. 2015; 133: 37-48.
30. Hirase K, Ikeda T, Sotozono C, et al. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. Arch Ophthalmol. 1998; 116(6): 738-741.
31. Batsos G, Christodoulou E, Christou EE, et al. Vitreous inflammatory and angiogenic factors on patients with proliferative diabetic retinopathy or diabetic macular edema: the role of Lipocalin2. BMC Ophthalmol. 2022; 22(1): 496.
32. Ke D, Hong Y, Jiang X, Sun X. Clinical Features and Vitreous Biomarkers of Early-Onset Type 2 Diabetes Mellitus Complicated with Proliferative Diabetic Retinopathy. Diabetes Metab Syndr Obes. 2022; 15: 1293-1303.
33. Klimontov VV, Mavlyanova KR. Cytokines – promising diagnostic and prognostic biomarkers of microvascular complications of diabetes. Siberian Scientific Medical Journal. 2024; 44(2): 19-27. (In Russ.)
34. Sato T, Okazawa R, Nagura K, et al. Association between Systemic Factors and Vitreous Fluid Cytokines in Proliferative Diabetic Retinopathy. J Clin Med. 2023; 12(6): 2354.
35. Ehlers JP, Dupps WJ, Kaiser PK, et al. The Prospective Intraoperative and Perioperative Ophthalmic ImagiNg (PIONEER) study: 2-year results. Am J Ophthalmol. 2014; 158(5): 999-1007.
36. Ehlers JP, Griffith JF, Srivastava SK. Intraoperative optical coherence tomography during vitreoretinal surgery for dense vitreous hemorrhage in the PIONEER study. Retina. 2015; 35(12): 2534-2540.
37. Ehlers JP, Itoh Y, Xu LT, et al. Factors associated with persistent subfoveal fluid and complete macular hole closure in the PIONEER study. Invest Ophthalmol Vis Sci. 2014; 56(2): 1141-1146.
38. Vujosevic S, Bini S, Midena G, et al. Hyperreflective Intraretinal Spots in Diabetics without and with Nonproliferative Diabetic Retinopathy: An In Vivo Study Using Spectral Domain OCT. J Diabetes Res. 2013; 2013: 491835.
39. Vujosevic S, Toma C, Villani E, et al. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol. 2020; 57(3): 287-296.
40. Lee J, Moon BG, Cho AR, Yoon YH. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response. Ophthalmology. 2016; 123(11): 2368-2375.
41. Hsieh YT, Alam MN, Le D, et al. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema. Ophthalmol Retina. 2019; 3(10): 826-834.
42. Thompson IA, Durrani AK, Patel S. Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy. Eye. 2019; 33(4): 648-652.
43. Pfau M, Jolly JK, Wu Z, et al. Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. Prog Retin Eye Res. 2021; 82: 100907.
44. Vujosevic S, Midena E, Pilotto E, et al. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci. 2006; 47(7): 3044-3051.
45. Schreur V, van Asten F, Ng H, et al. Risk factors for the development of postoperative complications after pars plana vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmol. 2020; 98(4): e488-e494.
46. Petrachkov DV, Filippov VM, Balkar SSh. The effect of intraoperative use of angiogenesis inhibitors on the outcomes and complication rates of surgical treatment of proliferative diabetic retinopathy. Vestnik oftal’mologii. 2025; 141(2): 44–50. (In Russ.)
47. Shukla UV, Tripathy K. Diabetic retinopathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
48. Yang Q-H, Zhang Y, Zhang X-M, Li X-R. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and Meta-analysis. Int J Ophthalmol. 2019; 12: 302–11. doi: 10.18240/ijo.2019.02.19.


